mmissoldtw ←
Doug Drysdale3,697 posts
Doug Drysdale avatar

Doug Drysdale

@insidepharma

Biopharma Operator & Strategic Advisor | Founder, Katogen | Board Member | PubCo CEO | M&A, Capital Strategy | Read My Newsletter: bit.ly/4uXf4Ro

◷ Joined May 2011▧ 337 Photos and videos
Doug Drysdale avatar
Doug Drysdale@insidepharma·Nov 17

Most preclinical studies measure what happens to an animal model. This one looked at what changes inside individual brain cells. Researchers at Carleton University gave BETR-001 or LSD to adult male and female mice. They then used single-nucleus RNA sequencing to read gene activity cell by cell in the prefrontal and cingulate cortex. The work was supported in part by BetterLife, and the poster is being presented today at Neuroscience 2026 in Washington, D.C. BETR-001 and LSD produced broadly overlapping gene-expression changes tied to neuroplasticity and stress-hormone signaling. Both compounds affected genes involved in synaptic scaffolding and dendritic spine remodeling. The team also saw signatures linked to trafficking of TrkB, the receptor for BDNF and a key plasticity pathway. The response was large in both sexes, although many of the specific genes differed between males and females. This matters because earlier mouse studies showed BETR-001 has a non-hallucinogenic behavioral profile. Seeing plasticity-related biology without the hallucinations is the scientific premise of our program and remove many of the barriers associated with psychedelic treatments. We're preparing a planned IND submission in Q1 2027 for the preventive treatment of chronic cluster headache and chronic migraine - disorders affecting over 40mm people in the US alone. Link to press release: globenewswire.com/news-relea…

Post attachment
Doug Drysdale avatar
Doug Drysdale@insidepharma·Nov 11

Today is Veterans Day. Thank you to everyone who has served, and to the families who served alongside them. People don't often talk about what service can leave behind once someone comes home. Headache is one of the most common problems after a traumatic brain injury. For some veterans it never goes away, and it ends up shaping their work, their sleep and their family life for years. Too often they're told to live with it. They deserve better than that. They need clinicians who take headache seriously, research that includes them, and treatments that actually fit their lives. To every veteran and every family: thank you. We owe you more than one day a year.

Post attachment
Doug Drysdale avatar
Doug Drysdale@insidepharma·Nov 10

Chronic migraine has an odd definition when you read it closely. You qualify with headache on 15 or more days a month, for more than three months, and at least 8 of those days have to be migraine (ICHD-3). Put simply, that's someone who has a headache on more days than not. Most patients start out with episodic migraine. Every year a small share of them, roughly 2.5% in the American Migraine Prevalence and Prevention study, cross over into chronic. Overusing acute medication is one of the strongest risk factors for that switch, which leaves patients stuck. The drugs that get them through today can make next month worse. Preventive treatment has improved. The CGRP drugs were a real step forward, but plenty of people with chronic migraine still don't get enough relief. They are left managing a condition instead of having a life. That's why I think prevention is the right place to aim. We're developing BETR-001 as a preventive treatment for chronic migraine and chronic cluster headache.

Post attachment
Doug Drysdale avatar
Doug Drysdale@insidepharma·Nov 9

Another nine-figure round closed into the 5-HT2A neuroplastogen class this morning. Strategic pharma money, a crossover syndicate, and a Phase II in depression starting next year. That is real validation for an idea that was fringe five years ago. You can keep the synaptic remodelling and engineer out the hallucination, and there is now clinical safety data in people to support it. The neuroplastogen thesis is a cortical 5-HT2A story. Dendritic spine density in the prefrontal cortex. Rapid, durable effects on mood, with an argument extending into neurodegeneration. It is a plasticity mechanism pointed at circuits that have gone wrong. Headache is different pharmacology. The validated target set there is trigeminovascular: 5-HT1B, 1D and 1F. That is what triptans and ditans act on. A compound with 5-HT2A activity can sit alongside that chemistry, but it won't carry a headache program on its own. Which means the scaffold decides the indication. A tryptamine engineered for 5-HT2A selectivity is a mood and neurodegeneration asset. An ergoline carries the 5-HT1 agonism as well, which is why that chemistry keeps reappearing in headache. The capital flowing into this class helps everyone working on serotonergic plasticity. It also raises the bar. Being non-hallucinogenic with receptor selectivity and a matching indication are what differentiates.

Post attachment
Doug Drysdale avatar
Doug Drysdale@insidepharma·Nov 5

Today @BetterLifeBio welcomes Henry Chow, CPA, CA, to our Board of Directors. Henry founded Saturna Group in 2008. The firm is registered with CPAB and audits around 70 public companies. He brings more than 25 years of public company audit work, including US GAAP reporting and SOX 404 internal controls. Henry will stand for election at our AGM on December 9. I also want to thank Tony Pullen, who stepped down from the Board yesterday. Tony backed BetterLife when it was a much smaller company and supported the move to a focused neurology developer. I am happy that he has decided to stay with us as an advisor. newsfilecorp.com/release/322…

Financial Times avatar
⟳ Doug Drysdale retweeted
Financial Times@FT·Nov 3

FT Exclusive: CVS Health is plotting a break-up of its $117bn healthcare empire, separating its retail pharmacy chain from its insurance business in what would be one of the largest corporate splits of all time. ft.trib.al/ZlfmGt9

Post attachment
Daphne Zohar avatar
⟳ Doug Drysdale retweeted
Daphne Zohar@daphnezohar·Oct 30

AI will be hugely impactful but I haven’t yet heard a convincing answer to the question of what differentiates an “AI” drug devt company from everyone else when we all have access to AI and new models are evolving so quickly. On a related note, @LifeSciVC has a nice piece today on near-term impacts of AI (eg overcrowding around validated targets). lifescivc.com/2026/10/the-fr…

Peter H. Diamandis, MD avatar
⟳ Doug Drysdale retweeted
Peter H. Diamandis, MD@PeterDiamandis·Oct 28

Every religion in history has promised miracles and warned of the apocalypse. Anthropic is the first to file both with the SEC.

Doug Drysdale avatar
Doug Drysdale@insidepharma·Oct 28

HHS issues temporary enforcement discretion policy for 503A compounding of six peptides (not an approval, not a bulks-list addition) On October 28, 2026, HHS announced the availability of an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (FR Doc. 2026-22192, RIN 0910-ZD94). The Federal Register notice is scheduled for October 30. Under the policy, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound drug products using certain peptide bulk substances while FDA continues formal rulemaking on the 503A bulks list. This is an interim measure only. The six peptides covered (those recommended by the Pharmacy Compounding Advisory Committee in July 2026): •BPC-157 •Epitalon •KPV •MOTS-c •Semax •TB-500 These remain unapproved drugs. The policy does not constitute FDA approval, does not add them to the 503A bulks list (21 CFR 216.23), and does not apply to research-use-only products, dietary supplements, or 503B outsourcing facilities. Key conditions for the policy to apply include: •Patient-specific prescription •Bulk substance from an FDA-registered manufacturer (section 510) with a valid certificate of analysis documenting identity, purity, potency, and absence of harmful contaminants •Generally one active ingredient per preparation •Route-of-administration limits specified in the policy’s Appendix B (examples: BPC-157 for subcutaneous, intramuscular, oral, or topical; TB-500 and MOTS-c for subcutaneous or intramuscular injectables; Semax for intranasal; KPV for topical or oral) •Reporting of serious adverse events and product quality issues to FDA (MedWatch) and relevant states •Specific labeling (“This is a compounded drug product. Not for resale”) and other 503A requirements HHS states the policy aims to expand patient access while discouraging use of certain research-use-only peptides from foreign manufacturers that pose quality and safety risks. It can be revisited if safety signals or product-quality issues arise. FDA scientists had previously recommended against including these substances due to limited human data; the advisory committee votes were non-binding. In short: this creates a temporary, regulated pathway for prescription compounding of these six peptides under strict quality and reporting safeguards—not a free pass, not formal approval, and not a permanent change to the 503A list.

Harry Kane avatar
⟳ Doug Drysdale retweeted
Harry Kane@HKane·10 Oct 2022

I'm very proud to launch the Harry Kane Foundation - it marks the start of a journey for me as my Foundation aims to transform a generation’s thinking about mental health.

1:55
Bryan Johnson avatar
⟳ Doug Drysdale retweeted
Bryan Johnson@bryan_johnson·Oct 25

Another win for psilocybin In 9 Parkinson's patients... GDF15 fell > 17.4% after 10 mg > 13.9% after 25 mg High GDF15 signals mitochondrial failure and neurodegeneration. Inflammation also declined: > IL-6: −17% > IL-8: −20% > hsCRP: −9.6% > IL-10: +2.7% (anti-inflammatory)

Post attachment
Doug Drysdale avatar
Doug Drysdale@insidepharma·Oct 23

Roughly 1.1 billion people live with migraine. For most it's an occasional bad day, but for some patients it takes more than half the month, even after the older preventives and the newer CGRP drugs. Many of these patients keep having frequent attacks after several preventives and need new options. Here's why I think BETR-001 deserves a serious test in those patients. First, the targets have a track record. BETR-001 is an agonist at 5-HT1B, 1D and 1F, the receptors triptans and lasmiditan already act on. We know that biology works for migraine. We aren't betting on an unproven pathway. Second, it adds something those drugs don't. It's also an agonist at 5-HT2A, the receptor linked to neural plasticity as seen with psychedelics. Third, the practical profile is designed for real life. It's an oral capsule, taken at home. Preclinical work shows it doesn't agonize 5-HT2B, the receptor that has caused cardiac safety trouble for some other drugs, and it isn't hallucinogenic. Fourth, there's an early human signal. A 2010 pilot by Karst and colleagues gave a racemic version of this compound to patients with cluster headache. We're targeting the IND for Q1 2027, and then into the clinic.

Post attachment